Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen.

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Wegovy will be available in five dose strengths in India, with 0.25 mg, 0.5 mg and 1 mg versions priced at 4,336.25 rupees ($50.71), the company said. The monthly cost would be 17,345 rupees ...

GLP-1 drugs may be hailed as a medical breakthrough in obesity care, but Indian experts warn they are no cosmetic quick-fix.

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...

Danish drugmaker Novo Nordisk (NOV: N) has filed for European approval of a higher-dose version of its obesity treatment ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...